mepolizumab sold brand name nucala glaxosmithkline humanized monoclonal antibody used treatment severe eosinophilic asthma eosinophilic granulomatosis hypereosinophilic syndrome recognizes blocks signalling protein immune system common side effects include headache injection site reactions back mepolizumab approved us food drug administration fda maintenance treatment severe asthma patients aged six older eosinophilic phenotype combination medicines used treat european union approved addon treatment severe refractory eosinophilic asthma studies mepolizumab cut necessity hospitalisation due asthma exacerbations half compared december fda expanded mepolizumabs indication treat adults eosinophilic granulomatosis polyangiitis rare autoimmune condition cause september fda expanded mepolizumabs indication treat adults children aged twelve years older hypereosinophilic syndrome hes six months longer without another identifiable nonblood related cause common side effects clinical trials included headache patients mepolizumab treatment versus placebo injection site reactions versus infections urinary tract versus lower respiratory tract eczema muscle spasms versus common side effects people hypereosinophilic syndrome hes include upper respiratory tract infection pain extremities hands legs single doses times usual therapeutic dose tolerated studies without significant side interaction studies conducted monoclonal antibodies interaction potential considered mepolizumab binds prevents binding receptor specifically interleukin receptor alpha subunit surface eosinophil white blood cells eosinophils play role inflammation associated asthma exact mechanism mepolizumab subcutaneous injection mepolizumab estimated bioavailability reaches highest blood plasma concentrations four eight days like antibodies degraded proteolytic enzymes biological halflife days average ranging days different substance kappa monoclonal antibody two heavy chains consisting amino acids two light chains consisting amino acids protein part molar mass kda sugar part phase iii clinical trials severe eosinophilic asthma completed fda approved november european commission granted marketing authorization valid throughout european union december mepolizumab approved medical use european union december september mepolizumab approved united states treat adults children aged twelve years older hypereosinophilic syndrome hes six months longer without another identifiable nonblood related cause mepolizumab evaluated randomized doubleblind multicenter placebocontrolled trial participants hypereosinophilic syndrome study participants randomly assigned receive mepolizumab placebo injection every four trial compared proportion subjects experienced hes flare treatment hes flare defined worsening clinical signs symptoms hes increasing eosinophils diseasefighting white blood cells least two trial compared proportions participants least one flare treatment period well time first fewer participants mepolizumab treatment group hes flares compared participants placebo group relative addition time first hes flare later average participants treated mepolizumab versus mepolizumab investigated investigation treatment atopic dermatitis hypereosinophilic syndrome hes eosinophilic esophagitis nasal polyposis eosinophilic granulomatosis polyangiitis chronic obstructive pulmonary disease immune activation dostarlimab ibalizumab httpsenwikipediaorgwikimepolizumab